Denali Therapeutics Inc. (NASDAQ:DNLI) Expected to Announce Earnings of -$0.56 Per Share

Equities analysts predict that Denali Therapeutics Inc. (NASDAQ:DNLIGet Rating) will post earnings of ($0.56) per share for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for Denali Therapeutics’ earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.87). Denali Therapeutics posted earnings per share of ($0.50) during the same quarter last year, which suggests a negative year over year growth rate of 12%. The business is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Denali Therapeutics will report full year earnings of ($2.68) per share for the current year, with EPS estimates ranging from ($3.01) to ($2.32). For the next year, analysts expect that the business will report earnings of ($2.57) per share, with EPS estimates ranging from ($3.30) to ($0.90). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Denali Therapeutics.

Denali Therapeutics (NASDAQ:DNLIGet Rating) last released its earnings results on Thursday, May 5th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). Denali Therapeutics had a negative net margin of 344.79% and a negative return on equity of 28.13%. The company had revenue of $42.10 million for the quarter, compared to the consensus estimate of $33.32 million. During the same quarter in the previous year, the company posted ($0.58) earnings per share. The business’s revenue was up 432.9% compared to the same quarter last year.

Several equities analysts have commented on DNLI shares. Wedbush decreased their target price on shares of Denali Therapeutics from $62.00 to $48.00 in a report on Friday, May 6th. The Goldman Sachs Group decreased their price objective on shares of Denali Therapeutics from $114.00 to $98.00 and set a “buy” rating on the stock in a research note on Monday, March 7th. Finally, TheStreet cut Denali Therapeutics from a “c-” rating to a “d” rating in a research note on Wednesday, March 2nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $81.67.

In related news, Director Marc Tessier-Lavigne sold 20,000 shares of the firm’s stock in a transaction on Wednesday, March 23rd. The stock was sold at an average price of $33.83, for a total transaction of $676,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 17.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. HM Payson & Co. bought a new stake in Denali Therapeutics during the 4th quarter worth approximately $26,000. Lindbrook Capital LLC acquired a new position in shares of Denali Therapeutics during the fourth quarter worth $27,000. Dark Forest Capital Management LP grew its stake in shares of Denali Therapeutics by 19,733.3% in the third quarter. Dark Forest Capital Management LP now owns 595 shares of the company’s stock worth $30,000 after purchasing an additional 592 shares during the last quarter. Patriot Financial Group Insurance Agency LLC increased its holdings in Denali Therapeutics by 125.3% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 811 shares of the company’s stock valued at $36,000 after purchasing an additional 451 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in Denali Therapeutics during the 3rd quarter worth $45,000. Institutional investors and hedge funds own 72.32% of the company’s stock.

DNLI stock traded up $1.03 during midday trading on Friday, reaching $22.86. The company had a trading volume of 1,006,021 shares, compared to its average volume of 546,280. The company has a market capitalization of $2.81 billion, a price-to-earnings ratio of -9.77 and a beta of 1.90. Denali Therapeutics has a 1-year low of $20.24 and a 1-year high of $79.70. The stock has a 50 day moving average price of $29.38 and a 200-day moving average price of $37.21.

About Denali Therapeutics (Get Rating)

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Recommended Stories

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with's FREE daily email newsletter.